Therapeutic potential of targeting TNF/TNFR family members in asthma

Immunotherapy

Volumn 3, Issue 8, 2011, Pages 919-921

  Doherty, Taylor A ^a   Croft, Michael ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

airway remodeling; asthma; fibrosis; LIGHT; OX40

Indexed keywords

CD134 ANTIGEN; CD30 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CORTICOSTEROID; HERPESVIRUS ENTRY MEDIATOR; HERPESVIRUS ENTRY MEDIATOR LIGAND; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; LYMPHOTOXIN BETA RECEPTOR; MEPOLIZUMAB; OX40 LIGAND; THYMIC STROMAL LYMPHOPOIETIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR;

AIRWAY OBSTRUCTION; AIRWAY REMODELING; ANGIOGENESIS; ASTHMA; BRONCHUS HYPERREACTIVITY; DISEASE SEVERITY; EOSINOPHIL; FIBROSIS; HUMAN; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; T LYMPHOCYTE; TH2 CELL;

ANIMALS; ASTHMA; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80051869977     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.88     Document Type: Review

References (21)

1. Broide DH. Immunologic and inflammatory mechanisms that drive asthma progression to remodeling. J. Allergy Clin. Immunol. 121(3), 560-570 (2008). (Pubitemid 351323873)
2. Girodet PO, Ozier A, Bara I et al. Airway remodeling in asthma: new mechanisms and potential for pharmacological intervention. Pharmacol. Ther. 130(3), 325-337 (2011).
3. Halwani R, Al-Muhsen S, Al-Jahdali H, Hamid Q. Role of transforming growth factor-b in airway remodeling in asthma. Am. J. Respir. Cell Mol. Biol. 44(2), 127-133 (2011).
4. Salek-Ardakani S, Song J, Halteman BS et al. OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation. J. Exp. Med. 198(2), 315-324 (2003). (Pubitemid 36987856)
5. Soroosh P, Doherty TA, So T et al. Herpesvirus entry mediator (TNFRSF14) regulates the persistence of T helper memory cell populations. J. Exp. Med. 208(4), 797-809 (2011).
6. Doherty TA, Soroosh P, Khorram N et al. The tumor necrosis factor family member LIGHT is a target for asthmatic airway remodeling. Nat. Med. 17(5), 596-603 (2011).
7. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat. Rev. Immunol. 9(4), 271-285 (2009).
8. Burgess JK, Carlin S, Pack RA et al. Detection and characterization of OX40 ligand expression in human airway smooth muscle cells: a possible role in asthma? J. Allergy Clin. Immunol. 113(4), 683-689 (2004). (Pubitemid 38530424)
9. Jember AG, Zuberi R, Liu FT, Croft M. Development of allergic inflammation in a murine model of asthma is dependent on the costimulatory receptor OX40. J. Exp. Med. 193(3), 387-392. (2001). (Pubitemid 32524521)
10. Ito T, Wang YH, Duramad O et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J. Exp. Med. 202(9), 1213-1223 (2005). (Pubitemid 41586952)
11. Ying S, O'Connor B, Ratoff J et al. Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. J. Immunol. 174(12), 8183-8190 (2005). (Pubitemid 40806330)
12. Siddiqui S, Mistry V, Doe C et al. Airway wall expression of OX40/OX40L and interleukin-4 in asthma. Chest 137(4), 797-804 (2010).
13. Zhou B, Comeau MR, De Smedt T et al. Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nat. Immunol. 6(10), 1047-1053 (2005). (Pubitemid 41486190)
14. Seshasayee D, Lee WP, Zhou M et al. In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation. J. Clin. Invest. 117(12), 3868-3878 (2007). (Pubitemid 350224096)
15. Duan W, So T, Croft M. Antagonism of airway tolerance by endotoxin/lipopolysaccharide through promoting OX40L and suppressing antigen-specific Foxp3+ T regulatory cells. J. Immunol. 181(12), 8650-8659 (2008).
16. Duan W, Mehta AK, Magalhaes JG et al. Innate signals from Nod2 block respiratory tolerance and program T(h)2-driven allergic inflammation. J. Allergy Clin. Immunol. 126(6), 1284-1293 (2010).
17. Jung HW, La SJ, Kim JY et al. High levels of soluble herpes virus entry mediator in sera of patients with allergic and autoimmune diseases. Exp. Mol. Med. 35(6), 501-508 (2003). (Pubitemid 38129314)
18. Hastie AT, Moore WC, Meyers DA et al. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J. Allergy Clin. Immunol. 125(5), 1028-1036 (2010).
19. Nair P, Pizzichini MM, Kjarsgaard M et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N. Engl. J. Med. 360(10), 985-993 (2009).
20. Haldar P, Brightling CE, Hargadon B et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 360(10), 973-984 (2009).
21. Clienti S, Morjaria JB, Basile E, Polosa R. Monoclonal antibodies for the treatment of severe asthma. Curr. Allergy Asthma Rep. 11(3), 253-260 (2011).